id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
3231916,abfde80a-14ab-40ce-87b1-1c455f9a501a,Q3,HOLLAND & KNIGHT LLP,18466,VIATRIS INC,2024,third_quarter,PHA,"Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-02T10:51:07-04:00
3232107,5fc1df71-9268-4dc6-8341-726e03734bf0,Q3,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2024,third_quarter,PHA,Monitor Health Data Policy.,"Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-02T16:03:39-04:00
3232230,41da2eef-7e12-4553-98b8-76dbc47f668c,Q3,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2024,third_quarter,PHA,Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.,"HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2024-10-03T11:00:22-04:00
3232358,7a568241-fed2-47a6-a77f-011f95e735eb,Q3,MCDERMOTT+ LLC,401103287,ALLIANCE FOR RURAL HOSPITAL ACCESS,2024,third_quarter,PHA,Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.,"HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2024-10-03T15:36:27-04:00
3232398,a82f58a9-86a4-4006-b2f7-3f0d42e8c4d1,Q3,AEGIS LLC,401108688,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2024,third_quarter,PHA,"PBM reforms. 340B. IRA implementation. Drug pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.2880 - Protecting Patients Against PBM Abuses Act. S.2973 - Modernizing and Ensuring PBM Accountability Act. H.R.830 - HELP Copays Act. H.R.7085 - BIOSECURE Act. S.127 - Pharmacy Benefit Manager Transparency Act of 2023. S.1339 - Pharmacy Benefit Manager Reform Act H.R.3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-03T17:08:29-04:00
3232400,0ee47b02-acb4-4961-b976-2316fb770b61,Q3,AEGIS LLC,401108688,"TRIS PHARMA, INC.",2024,third_quarter,PHA,ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving).,"HOUSE OF REPRESENTATIVES,Natl Highway Traffic Safety Administration (NHTSA),SENATE",50000,,0,0,2024-10-03T17:09:00-04:00
3232406,dd0f4f46-dcce-4e2e-87e7-fb9ecb0a5bca,Q3,2359 STRATEGIES,401106114,TRAVERE THERAPEUTICS,2024,third_quarter,PHA,Orphan Drug Act,"HOUSE OF REPRESENTATIVES,SENATE",12000,,0,0,2024-10-03T18:25:31-04:00
3232460,aa501068-6234-4921-9d9f-8075fee452ad,Q3,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,401103605,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,2024,third_quarter,PHA,"Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains","HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2024-10-04T08:07:29-04:00
3232731,3f10a316-e565-4ea3-aa28-a064a7e54a8a,Q3,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2024,third_quarter,PHA,"H. R. 9747 - Continuing Appropriations and Extensions Act, 2025 - Issues related to funding government departments and agencies responsible for administering programs that support prescription drug coverage. CMS Rules and Regulations focused on the promulgation of the Medicare Part D program. S. 1542 - The DRUG Act - Issues related to ensuring that policies contemplated by Congress allow entities providing coverage of prescription medications have the tools they need to keep drugs affordable and accessible in the commercial market. H.R. 7623 - Telehealth Modernization Act of 2024 - Support for the underlying telemedicine extension, yet concern for the commercial delinking offset included in the legislation. S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees. S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients. H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare. S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications. S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. Issues related to prescription drug supply chain integrity and transparency. Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2024-10-05T12:31:06-04:00
3232899,c123c323-9dd3-40a6-b0f7-62efe24f1e91,Q3,"MASON STREET CONSULTING, LLC",401105150,CAPITAL RX INC.,2024,third_quarter,PHA,PBM Reform.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-07T06:14:00-04:00
3233064,bf2a57bc-a7df-4ddc-881f-661964abada3,Q3,DAVE KOLBE CONSULTING,401104329,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2024,third_quarter,PHA,H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-07T12:09:49-04:00
3233221,9e65d762-93ce-43dc-ac10-4e30a977303f,Q3,RAY ANDERSON,401105487,340B HEALTH,2024,third_quarter,PHA,"Contract Pharmacy-HR 7635, The 340B PATIENTS Act of 2024 340B Transparency-No legislation yet Contract Pharmacy Protect 340B-340B Patients Act 340B Transparency-Opposition to H.R. 3290 (overly burdensome reporting legislation that distorts the 340B program) Letter to HHS Secretary Becerra","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES",,,0,0,2024-10-07T17:36:02-04:00
3233222,2f6bd4af-77c1-404f-893f-69ad77de8053,3A,RAY ANDERSON,401105487,340B HEALTH,2024,third_quarter,PHA,"Contract Pharmacy-HR 7635, The 340B PATIENTS Act of 2024 340B Transparency-No legislation yet Contract Pharmacy Protect 340B-340B Patients Act 340B Transparency-Opposition to H.R. 3290 (overly burdensome reporting legislation that distorts the 340B program) Letter to HHS Secretary Becerra","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES",,15000,0,0,2024-10-07T18:14:14-04:00
3233228,2e974ce4-4284-4b67-b9f7-c20e02837748,Q3,STUMPTOWN STRATEGIES,401106433,PRIME THERAPEUTICS,2024,third_quarter,PHA,Introduction to Prime to Members of the 118th Congress Monitoring PBM Legislation,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-10-07T18:31:05-04:00
3233576,47d565fb-92e3-43d0-b1e5-fcde65ea19f1,Q3,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,11003,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,2024,third_quarter,PHA,CCAGW Hosts Briefing on 340B Drug Discount Program CCAGW Hosts Briefing on 340B Drug Discount Program CCAGW Shares Blog Post on 340B Drug Discount Program CCAGW Shares Blog Post on 340B Drug Discount Program,"HOUSE OF REPRESENTATIVES,SENATE",,420000,0,0,2024-10-08T13:23:37-04:00
3233591,1ea0688d-ff91-4ca2-bb61-687694468c2a,Q3,POLSINELLI PC,314911,RESQ PHARMA,2024,third_quarter,PHA,FDA Regulatory Issues,HOUSE OF REPRESENTATIVES,10000,,0,0,2024-10-08T14:01:14-04:00
3233713,d3b37f5c-f3a4-4385-a7ba-f7511d0ac52d,Q3,ACG ADVOCACY,2057,WALGREEN CO.,2024,third_quarter,PHA,Drug pricing policy issues. Data privacy. Provider status legislation. Counterfeiting issues.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-08T15:11:13-04:00
3233733,5810ed86-ee6c-4267-bf85-3f05ecb21d38,Q3,OMEGA STRATEGIES LLC (DC),401108551,ON DEMAND PHARMACEUTICALS,2024,third_quarter,PHA,Advocated on issues related to appropriations and defense industrial base policy.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-10-08T15:28:16-04:00
3233899,9017dcaa-8a03-47bb-b194-9dad215a1d6e,Q3,WEST FRONT STRATEGIES LLC,401103493,WALGREEN CO.,2024,third_quarter,PHA,"Issues related to pharmacy, military pharmacies, pharmacist provider status, and Medicare reimbursement, including Equitable Community Access to Pharmacist Services Act (H.R. 1770 and S. 2477).","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-08T22:32:34-04:00
3234073,237e24fd-86f1-4931-90d0-069a0625ad1e,Q3,"FAMILIES USA FOUNDATION, INC.",14108,FAMILIES USA FOUNDATION INC,2024,third_quarter,PHA,"s.150Affordable Prescriptions for Patients Act of 2023To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.","HOUSE OF REPRESENTATIVES,SENATE",,10000,0,0,2024-10-09T11:10:22-04:00
3234280,168d625f-d2f9-4dc8-a36a-6fc2e4432254,Q3,LMH STRATEGIC SOLUTIONS,401108183,"AVADEL PHARMACEUTICALS, PLC",2024,third_quarter,PHA,Prescription Drug Competition Issues. H.R.4692/S.574 - Increasing Prescription Drug Competition Act.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-10-09T14:52:45-04:00
3234284,b3b24423-a540-4314-acea-fa693e033887,Q3,LMH STRATEGIC SOLUTIONS,401108183,GLAXOSMITHKLINE LLC,2024,third_quarter,PHA,"General healthcare issues impacting GSK. H.R.7085 - BIOSECURE Act. H.R.830 - HELP Copays Act. H.R.5378 - Lower Costs, More Transparency Act. S.1542 - DRUG Act.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-09T14:55:58-04:00
3234296,32568a51-1d72-461e-b2d3-5bf7c974e63b,Q3,LMH STRATEGIC SOLUTIONS,401108183,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2024,third_quarter,PHA,Prescription drug payment reform. Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-10-09T15:01:37-04:00
3234400,c536a96f-1f81-489e-bc18-597332cb851f,Q3,"CASSIDY & ASSOCIATES, INC.",8453,"HIMS & HERS HEALTH, INC. (FORMERLY HIMS, INC)",2024,third_quarter,PHA,Compounding / telehealth,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-09T16:18:43-04:00
3234642,7b293afd-980f-484b-80dc-7d24c594b9e9,Q3,BUCHANAN INGERSOLL & ROONEY PC,55291,AIM IMMUNOTECH INC.,2024,third_quarter,PHA,Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-10-10T10:53:21-04:00
3234695,2ecc71b6-e867-41db-bea2-87f04d4c49a9,Q3,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2024,third_quarter,PHA,OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. Proposed rule for Nonprescription Drug Product with an Additional Condition for Nonprescription Use H.R. 2964/S. 1350 - The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act FDA Nonprescription Drugs Advisory Committee Meeting on Phenylephrine Activities related to Over-the-Counter Monograph Drug User Fee Drug Enforcement Administration Pseudoephedrine quotas,"Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",118712,,0,0,2024-10-10T11:25:08-04:00
3234723,5d0d038b-24b9-4332-a09c-2ef173324e0a,Q3,MR. H.R. BERT PENA,400323519,MARGO RX LLC(DBA RICHARD'S PHARMACY),2024,third_quarter,PHA,PBM AND DRUG PRICES,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES",,,0,0,2024-10-10T12:11:31-04:00
3234879,c353f91b-f215-4d16-bab3-918b19ee2e28,Q3,THORSEN FRENCH ADVOCACY LLC,400599826,HEALTHCARE DISTRIBUTION ALLIANCE,2024,third_quarter,PHA,Drug Shortages.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-10T14:10:28-04:00
3234908,b96251e3-9e9e-49a5-b942-869df3c9e956,Q3,THORSEN FRENCH ADVOCACY LLC,400599826,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2024,third_quarter,PHA,Issues related to drug pricing. Issues realted to anti-competitive tactics in the pharmaceutical marketplace.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-10T14:18:17-04:00
3235880,96d3d243-be3d-4ccb-bfea-b624fcd99200,Q3,TRUSYNERGY,401107715,BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.),2024,third_quarter,PHA,"Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 25 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-10-12T11:56:34-04:00
3235996,6211d5ab-e322-4f2a-bece-cafafdedff54,Q3,KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS),401105192,CVS HEALTH,2024,third_quarter,PHA,"Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-12T19:01:42-04:00
3236983,cbb39a2e-f809-4de9-8821-ce3a8958f6cc,Q3,PRIME POLICY GROUP,400532589,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2024,third_quarter,PHA,H.R.1770 - Equitable Community Access to Pharmacist Services Act; PBM reform; S.2666 - EPCS 2.0 Act,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2024-10-14T14:32:25-04:00
3236989,644687ac-0f20-49e8-b4ba-0e5e5cc701ac,Q3,WINNING STRATEGIES WASHINGTON,50796,KALEO,2024,third_quarter,PHA,"Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-10-14T14:36:26-04:00
3237026,e7da9a39-e368-4e17-8d77-ba84853b14b2,Q3,RESOLUTE-DC,401106654,MODEL MEDICINES,2024,third_quarter,PHA,"Introduce Model Medicines and how the company is innovating at the intersection of data science, biology and drug development.","Health & Human Services, Dept of (HHS)",,,0,0,2024-10-14T14:53:18-04:00
3237043,5e399cc4-8a2a-4f4d-bbd3-a910db5ffb8f,3T,PRIME POLICY GROUP,400532589,"QUVA PHARMA, INC.",2024,third_quarter,PHA,"Legislation and regulation impacting outsourcing facilities regulated under Section 503B under the Federal Food, Drug, and Cosmetic Act","Centers For Medicare and Medicaid Services (CMS),SENATE",50000,,0,1,2024-10-14T15:03:29-04:00
3237046,4b4c25ef-6366-4f5e-93df-35fa4f4389a4,Q3,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2024,third_quarter,PHA,"IPC supports Drug Transparency in Medicaid Act (H.R. 1613) ICP supports Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act (HR 3561) IPC supports Drug Transparency in Medicaid Act (S. 1038) IPC supports The Modernizing and Ensuring PBM Accountability Act (S 2973) IPC supports Pharmacy and Medically Underserved Areas Enhancement Act (S 1491) IPC supports Protecting Patients Access to Pharmacy Act (S. 2052) IPC supports The Health Care Price Transparency Act (H.R. 4822) IPC supports Lower Cost, More Transparency Act (LCMT) (H.R. 5378) IPC supports Protecting Patients Against PBM Abuses Act (H.R. 2880) IPC Transparency and Fairness for Pharmacies Act (H.R. 5393) IPC supports Senate Bi-Partisan Working Group for 340B Reform - RFI response. IPC Supports FDA - Development of Small Dispensers Assessment Under the Drug Supply Chain Security Act; Request for Comments (FDA-2023-N-3103) IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC opposes S. 1339 Pharmacy Benefits Reform Act - because it may preempt state PBM laws relating to ERISA. IPC supports S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act IPC supports S. 127 Pharmacy Benefit Manager Transparency Act IPC supports (H.R. 1770/S. 2477) The Equitable Community Access to Pharmacists Services Act IPC supports FDA delay of DSCSA enhanced data compliance-request for comments CMS Implementation of PY 2024 Medicare Part D drug rule-comments CMS Implementation of drug provisions of the IRA 2022-comments","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2024-10-14T15:05:11-04:00
3237353,d0d43f3e-69ee-4bee-a1a8-7c8af6301796,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,ABBOTT LABORATORIES,2024,third_quarter,PHA,"Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R.1770/S.2477, the Equitable Community Access to Pharmacist Services Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-14T18:47:46-04:00
3237527,eb0bc388-daeb-462b-9d23-3ade4037536d,Q3,COREWELL HEALTH,298455,COREWELL HEALTH,2024,third_quarter,PHA,340B PBM Reform/Oversight Transparency and high costs associated with prescription drugs,"HOUSE OF REPRESENTATIVES,SENATE",,140000,0,0,2024-10-15T08:32:44-04:00
3237784,e86e2c46-950b-485d-b41e-eccb79174d92,Q3,"NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)",28264,NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD),2024,third_quarter,PHA,Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Lab-developed tests.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,60000,0,0,2024-10-15T10:45:24-04:00
3238019,b1823a99-db7f-4d8b-a94e-accf6a547d25,Q3,NATIONAL RIGHT TO LIFE COMMITTEE,28481,NATIONAL RIGHT LIFE COMMITTEE,2024,third_quarter,PHA,"Contacts in support of proposed rule, ""Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation,"" 88 FR 12875 (March 1, 2023), (RIN): 1117-AB40, Docket ID DEA-407 due to impact of assisted suicide drugs. Contacts regarding vending machine dispensing of chemical abortion drugs.","Drug Enforcement Administration (DEA),SENATE",,38000,0,0,2024-10-15T11:58:39-04:00
3238046,29501d1c-59fa-4cdf-ad98-2c1c133a71c4,Q3,NATIONAL RIGHT TO LIFE COMMITTEE,28481,NATIONAL RIGHT LIFE COMMITTEE,2024,third_quarter,PHA,"Contacts in support of proposed rule, ""Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation,"" 88 FR 12875 (March 1, 2023), (RIN): 1117-AB40, Docket ID DEA-407 due to impact of assisted suicide drugs. Contacts regarding vending machine dispensing of chemical abortion drugs.","Drug Enforcement Administration (DEA),SENATE",,38000,0,0,2024-10-15T12:05:53-04:00
3238248,0650c181-03cb-4ec0-b6c3-e4019013d8bd,Q3,MANATOS & MANATOS,23634,VANDA PHARMACEUTICALS INC,2024,third_quarter,PHA,FDA approval of specific medical drugs,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-10-15T13:22:20-04:00
3238422,49a05523-f710-4e40-bfb3-b9d419486ad5,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,WALGREEN CO.,2024,third_quarter,PHA,H.R. 1770 Equitable community access to pharmacist services act Issues related to drug pricing reform and transparency Issues related to access and distribution of pharmaceutical products Issues related to Artificial Intelligence in healthcare,HOUSE OF REPRESENTATIVES,50000,,0,0,2024-10-15T14:22:20-04:00
3238453,1253ee57-5b3a-4bea-8b8e-378d22f74358,Q3,PANNONE LOPES DEVEREAUX & O'GARA LLC,401105501,AMGEN,2024,third_quarter,PHA,Prescription drug pricing.,,9000,,0,0,2024-10-15T14:26:17-04:00
3238673,deed46c0-9af6-475c-b873-34577378d9cc,Q3,PUBLIC CITIZEN,32362,PUBLIC CITIZEN,2024,third_quarter,PHA,"government support for flu vaccine development, government use patent licensing; S.954 Affordable Insulin Now Act, march-in rights; S.954, Medicare drug price negotiation and inflationary rebate expansion, pharmacy benefit managers; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, vaccine disinformation, weight loss drug pricing, DTC pharmaceutical advertising, Medicare drug price negotiation and inflationary rebate expansion; government use patent licensing; march-in rights; reasonable pricing and access conditions, S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, GLP-1 pricing and licensing, DOD prescription drug international reference pricing; misleading social media prescription drug promotion penalties, social media prescription drug promotion harms, Improving Medicare Coverage Act.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,65265,0,0,2024-10-15T15:11:52-04:00
3238697,9e19ad8c-dfed-4776-9085-2cd78e4297b4,Q3,WEST FRONT STRATEGIES LLC,401103493,VIATRIS INC,2024,third_quarter,PHA,Issues related to e-labeling.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-15T15:24:42-04:00
3238812,9e969425-3fac-4b13-8ec8-e018a408ed00,Q3,"1607 STRATEGIES, LLC",401105461,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,2024,third_quarter,PHA,"S. 2793, Modernizing and Ensuring PBM Accountability Act, all provisions. H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act, all provisions.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-15T16:15:41-04:00
3239017,8731a176-e643-4eb4-9b18-69cf603b9d2b,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,AMERICAN KRATOM ASSOCIATION,2024,third_quarter,PHA,"Issues related to Food and Drug Administration regulatory and consumer access. Issues related to H.R. 5905, Federal Kratom Consumer Protection Act, and the Fiscal Year 2025 Agriculture Appropriations bills.",HOUSE OF REPRESENTATIVES,50000,,0,0,2024-10-15T17:01:57-04:00
3239103,6236de19-7dda-4276-a7d9-bf1ee1cbaf55,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION),2024,third_quarter,PHA,"Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R.1770/S. 2477, The Equitable Community Access to Pharmacist Services Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-15T17:22:53-04:00
3239420,3c80b395-c6cd-490c-9206-c6db8c84b3bd,Q3,WAKEFERN FOOD CORP.,400588798,WAKEFERN FOOD CORP.,2024,third_quarter,PHA,"Comprehensive pharmacy benefit manager (PBM)/DIR fee reform H.R. 5378 - ""Lower Costs, More Transparency Act"" S. 3430 - ""Better Mental Health Care, Lower-Cost Drugs, and Extenders Act"" S. 2973 - ""Modernizing and Ensuring PBM Accountability Act"" Legislative measures add more transparency","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-10-16T09:23:21-04:00
3239492,37a1cfa6-d120-4b43-a69e-5b99aab72075,Q3,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2024,third_quarter,PHA,N/A,"HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2024-10-16T09:47:58-04:00
3239582,c67e6031-2714-40fa-a0ac-5ce4a88d7cc0,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2024,third_quarter,PHA,General issues related to Over-The-Counter (OTC) pharmaceutical supply chain.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-16T10:14:21-04:00
3239687,156d758b-e789-4266-8548-301af67f54e4,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CVS HEALTH,2024,third_quarter,PHA,"Issues related to drug pricing transparency. Issues related to pharmacy benefit managers. Issues related to testing, vaccination and treatment including H.R.1770 and S.2477, the Equitable Community Access to Pharmacist Services Act. Issues related to pharmaceutical access and affordability. Issues related to pharmaceutical supply chains.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-16T10:43:33-04:00
3240093,c26f9816-cde1-475c-ac2e-1dc6f2f72255,Q3,VENN STRATEGIES,65191,THE PERSONAL CARE PRODUCTS COUNCIL,2024,third_quarter,PHA,"Issues related to personal care products, including but not limited to sunscreen and the humane cosmetic acts.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-16T12:17:41-04:00
3240328,ff50a6fa-b248-48f0-a328-e12bcdbd361f,Q3,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2024,third_quarter,PHA,Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA),"Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,497548,0,0,2024-10-16T13:31:27-04:00
3241510,8a9b35ef-a6f8-4227-b453-a8e688ffad63,Q3,SHIONOGI INC.,401107081,SHIONOGI INC.,2024,third_quarter,PHA,"Pandemic preparedness; Antimicrobial resistance; Pandemic and All Hazards Preparedness Act (PAHPA) Reauthorization; PASTEUR Act (H.R. 2940, S. 1355); Rare Pediatric Disease Priority Review Voucher reauthorization. (H.R. 3433, HR 7384, S. 4583)","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,90000,0,0,2024-10-16T17:13:22-04:00
3241563,7c7e2bb8-867a-41e9-a5e0-36d95d716e31,Q3,PRINTING UNITED ALLIANCE,401105682,PRINTING UNITED ALLIANCE,2024,third_quarter,PHA,Retention of FDA regulations mandating use of pharmaceutical information and prescriber data on paper. Support of H.R. 1173 (118th Congress): Patients Right to Know Their Medication Act.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2024-10-16T17:32:24-04:00
3241669,e2d77a42-dbd5-406e-8eb6-fbbfa9ecde43,Q3,BLUE SHIELD OF CALIFORNIA,6518,BLUE SHIELD OF CALIFORNIA,2024,third_quarter,PHA,Affordable Care Act Tax Credits Pharmacy Benefit Manager Reforms,"HOUSE OF REPRESENTATIVES,SENATE",,120000,0,0,2024-10-16T19:18:44-04:00
3242154,7d3b1d21-97aa-4db0-bccc-842b46db6ba4,Q3,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2024,third_quarter,PHA,"Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act","HOUSE OF REPRESENTATIVES,SENATE",,1795000,0,0,2024-10-17T10:18:05-04:00
3242258,9bb791ee-4065-4998-8d7b-7d26e42db0d5,Q3,HEALTHSPERIEN,401103150,EXACT CARE PHARMACY,2024,third_quarter,PHA,Advocate for codifying definition for long-term care pharmacy in the home setting. (S. 1574) Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",35000,,0,0,2024-10-17T10:35:22-04:00
3242476,9e630b18-47d2-4797-94e8-9c4e584e7634,Q3,THE CONSILIO GROUP,400374717,PARATEK PHARMACEUTICALS,2024,third_quarter,PHA,"Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use","Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office",36000,,0,0,2024-10-17T10:58:19-04:00
3242571,456d88c8-3457-4f86-910c-ff855beeffa8,Q3,"WHITMER & WORRALL, LLC",292892,CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP),2024,third_quarter,PHA,Issues related to prescription drug pricing. S. 2305 Biosimilar Red Tape Elimination Act. S. 148 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 Ensuring Timely Access to Generics Act. S. 775/H.R. 3839 Increasing Transparency in Generic Drug Applications Act. S. 1214 Retaining Access and Restoring Exclusivity (RARE) Act.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-17T11:04:34-04:00
3242943,569604c7-864e-479c-b592-f3e430675e1f,Q3,WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH,401107274,WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH,2024,third_quarter,PHA,Any bills or provisions related to the 340b drug discount program.,"HOUSE OF REPRESENTATIVES,SENATE",,110000,0,0,2024-10-17T11:43:35-04:00
3243025,2d0d78e7-c653-4f44-bc03-b76d431b328b,Q3,CAPITOL COUNSEL LLC,313715,"EMD SERONO, INC.",2024,third_quarter,PHA,Issues regarding the availability and pricing of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-17T11:56:09-04:00
3243072,76755f1d-9041-46e8-84ef-72eca2eff8e8,Q3,ARNOLD & PORTER KAYE SCHOLER LLP,4301,"NOVO NORDISK, INC.",2024,third_quarter,PHA,Issues related to pharmacy benefit managers (PBMs) and the 340B Program.,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2024-10-17T12:04:10-04:00
3243197,49cd3f60-28c1-48bc-9674-3fcbc3b8a1c4,Q3,"POWERS PYLES SUTTER & VERVILLE, P.C.",32008,NATIONAL ASSOCIATION OF SPECIALTY PHARMACY,2024,third_quarter,PHA,Pharmacy market competition.,"Commerce, Dept of (DOC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE",120000,,0,0,2024-10-17T12:23:53-04:00
3243230,f026d099-3ca2-478b-aacc-dec97b131f22,Q3,"DESIMONE CONSULTING, LLC",400931695,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2024,third_quarter,PHA,"Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform; H.R. 2880, Protecting Patients Against PBM Abuses Act and H.R.5376, Share the Savings with Seniors Act. Issues related to 340B reform; H.R.8574, To amend the Public Health Service Act to reform the 340B drug pricing program, and for other purposes. Issues related to the Ensuring Pathways to Innovative Cures (EPIC) Act, H.R.7174.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-17T12:30:03-04:00
3243271,c8b572a7-46be-4d79-a1ad-2cbf2c27a5f3,Q3,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2024,third_quarter,PHA,Prescription Drug Pricing Reform; Pharmacy Benefit Managers; Delinking PBM language; Prior Authorization S. 1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage,"HOUSE OF REPRESENTATIVES,SENATE",,160000,0,0,2024-10-17T12:41:19-04:00
3243370,7508310f-3b3b-41f4-a4cf-48b28a6cebe2,Q3,"BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.",6382,BLUE CROSS AND BLUE SHIELD OF FLORIDA INC,2024,third_quarter,PHA,"Gene Therapies; Prescription Drug Affordability HR 6094, PROTECT Rare Act, by Rep. Doris Matsui (D-CA). To amend titles XVIII and XIX of the Social Security Act and title XXVII of the Public Health Service Act to refine the set of information sources for determining coverage of certain drugs and biologicals used in the treatment or management of a rare disease or condition. HR 9070, Affordable Prescriptions for Patients Act of 2024, by Rep. Darrell Issa (R-CA). To amend title 35, United States Code, to prohibit product hopping. S 150, Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping. S 775, Increasing Transparency in Generic Drug Applications Act, by Sen. Margaret Hassan (D-NH). To provide for increased transparency in generic drug applications. S 1542, DRUG Act, by Sen. Roger Marshall (R-KS). To improve services provided by pharmacy benefit managers.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,220000,0,0,2024-10-17T13:04:20-04:00
3243383,cc15e2f6-db22-467b-a5f9-37fec2f8ffe1,Q3,"HIGHMARK, INC.",18238,HIGHMARK INC,2024,third_quarter,PHA,"Issues: Insulin Copay Caps, Drug Pricing, Pharmacy Benefit Manager (PBM) Reform, Generic Drug Manufacturing, GLP-1s Bills: Senate Finance Committee PBM Reform Framework H.R. 5378 - The Lower Costs, More Transparency Act - A bill to require health care providers and insurers to disclose certain information about health care costs. It also establishes requirements for certain payment methodologies under Medicare and Medicaid and extends several public health programs. H.R. 1488/S. 954 - The Affordable Insulin Now Act -- A bill to provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. S. 127. - The Pharmacy Benefit Manager Transparency Act - This bill generally prohibits pharmacy benefit managers (PBMs) from engaging in certain practices when managing the prescription drug benefits under a health insurance plan, including charging the plan a different amount than the PBM reimburses the pharmacy. S.1339 - The Pharmacy Benefit Manager Reform Act - A bill to provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. H.R.2679 - The Pharmacy Benefits Manager Accountability Act - A bill to amend the Public Health Service Act, the Employee Retirement Income Security Act, and the Internal Revenue Code of 1984 to increase oversight of pharmacy benefits manager services, and for other purposes. H.R. 3561 - PATIENT Act of 2023 - This bill expands hospital price transparency requirements and establishes additional reporting requirements with respect to prescription drugs and pharmacy benefit managers (PBMs). H.R. 2630/S. 652 - The Safe Step Act -- This bill requires a group health plan to establish an exception to medication step-therapy protocol in specified cases. A medication step-therapy protocol establishes a specific sequence in which prescription drugs are covered by a group health plan or a health insurance issuer. H.R. 830/S. 1375 - The HELP Copays Act -- This bill requires health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. H.R. 2880 - Protecting Patients Against PBM Abuses Act -- This bill establishes requirements for Medicare pharmacy benefit managers (PBMs) with respect to remuneration, payments, and fees. Specifically, the bill restricts PBMs that are under contract with plans under the Medicare prescription drug benefit or Medicare Advantage from (1) receiving income for their services other than flat dollar amount service fees; (2) basing any service fees on the prices of covered drugs or any associated discounts, rebates, or other remuneration; (3) charging plan sponsors for ingredient costs or dispensing fees in amounts that are different than what is reimbursed to the pharmacy; or (4) reimbursing network pharmacies for less than that what is reimbursed to PBM-affiliated pharmacies.","HOUSE OF REPRESENTATIVES,SENATE",,130000,0,0,2024-10-17T13:04:52-04:00
3243400,42201d7e-20d1-488e-a1f9-d46a73243f79,Q3,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2024,third_quarter,PHA,H.R. 1839/S. 993 Combatting Illicit Xylazine Act H.R. 4531 SUPPORT Act,"HOUSE OF REPRESENTATIVES,SENATE",,330000,0,0,2024-10-17T13:08:47-04:00
3243418,14ff0b2a-4c81-4995-a51c-54ea22731eaf,Q3,GUIDEWELL MUTUAL HOLDING CORPORATION,401103191,GUIDEWELL MUTUAL HOLDING CORPORATION,2024,third_quarter,PHA,"Gene Therapies; Prescription Drug Affordability HR 6094, PROTECT Rare Act, by Rep. Doris Matsui (D-CA). To amend titles XVIII and XIX of the Social Security Act and title XXVII of the Public Health Service Act to refine the set of information sources for determining coverage of certain drugs and biologicals used in the treatment or management of a rare disease or condition. HR 9070, Affordable Prescriptions for Patients Act of 2024, by Rep. Darrell Issa (R-CA). To amend title 35, United States Code, to prohibit product hopping. S 150, Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping. S 775, Increasing Transparency in Generic Drug Applications Act, by Sen. Margaret Hassan (D-NH). To provide for increased transparency in generic drug applications. S 1542, DRUG Act, by Sen. Roger Marshall (R-KS). To improve services provided by pharmacy benefit managers.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,20000,0,0,2024-10-17T13:11:33-04:00
3243430,da94157a-cad7-487a-821c-035306e8c064,Q3,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2024,third_quarter,PHA,Monitoring biotech legislation; prescription drug prices; Infrastructure Legislation,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-10-17T13:13:43-04:00
3243690,429f7406-46a2-4fdf-85bb-c423ab3cfb30,Q3,NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION,27786,NATIONAL FAMILY PLANNING AND REPRODUCTIVE HEALTH ASSOCIATION,2024,third_quarter,PHA,340B drug pricing program,"Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-10-17T13:54:49-04:00
3243875,0f0b3377-e797-48a8-b699-69fa5a758241,Q3,ASSOCIATION FOR ACCESSIBLE MEDICINES,16032,ASSOCIATION FOR ACCESSIBLE MEDICINES,2024,third_quarter,PHA,Prescription Drug Costs. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. 180-Day Exclusivity. H.R.3839/S.775: Increasing Transparency in Generic Drug Applications Act. Generic Drug Procurement Language as it Relates to H.R.2670/S.2226 - National Defense Authorization Act for Fiscal Year 2024. S.1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023. H.R.6109: Producing Incentives for Long-term Production of Lifesaving Supply of Medicines (PILLS) Act. Drug Shortages. S.2362 - Drug Shortage Prevention Act. S.2305: Biosimilar Red Tape Elimination Act. FDA Inspections. Drug-Device Combination Products. Third Party Drug Quality Studies. H.R.1503/S.2916: Prescription Information Modernization Act of 2023. H.R.2880: Protecting Patients Against PBM Abuses Act.,"Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),HOUSE OF REPRESENTATIVES,SENATE",,530000,0,0,2024-10-17T14:11:49-04:00
3243910,26ed94f3-8db5-485d-9998-1020068ba080,Q3,THE MADISON GROUP,284050,WALGREEN CO.,2024,third_quarter,PHA,"Issues pertaining to the retail pharmacy industry, access to and delivery of COVID-19 vaccinations and pharmacy benefit managers (PBMs). H.R. 1770/S. 2477, the Equitable Community Access to Pharmacist Services Act;","Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2024-10-17T14:14:25-04:00
3243967,2f967441-211b-400d-91af-14e4a0fd4cd8,Q3,FORBES-TATE,400976792,INDEPENDENT PHARMACY COOPERATIVE,2024,third_quarter,PHA,"Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency and reform; Issues related to S.127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S.1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R.3561 - PATIENT Act of 2023; Issues related to S.2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R.5378 - the Lower Costs, More Transparency Act.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-17T14:20:50-04:00
3243985,81f1e378-a4e7-4d5b-8168-9a90fa9e71ef,Q3,60 PLUS ASSOCIATION,41988,60 PLUS ASSOCIATION,2024,third_quarter,PHA,"Urging Members of Congress and the Biden Administration to support and advance the Equitable Community Access to Pharmacist Services Act (H.R. 1770, S. 2477) to provide payment for essential pharmacist services under Medicare Part B and ensure pharmacists can continue to protect seniors from the threat of COVID-19, influenza, RSV, strep throat, pneumococcal, and hepatitis B.","HOUSE OF REPRESENTATIVES,SENATE,White House Office",,,0,0,2024-10-17T14:21:58-04:00
3244100,3f4b3b32-e3a8-4095-83d7-da3fe43cd798,Q3,ARENTFOX SCHIFF LLP,4208,"AMERICAN PHARMACY COOPERATIVE, INC.",2024,third_quarter,PHA,"Prescription drug pricing generally Pharmacy Benefit Manager (PBM) reform generally S. 2973 (Modernizing and Ensuring PBM Accountability Act), all provisions S. 1339 (Pharmacy Benefit Manager Reform Act), regarding Pharmacy Benefit Manager (PBM) reform S. 3430 (Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023), regarding Pharmacy Benefit Manager (PBM) reform H.R. 5378 (Lower Costs, More Transparency Act), regarding Pharmacy Benefit Manager (PBM) reform H.R. 6283 (DRUG Act), regarding Pharmacy Benefit Manager (PBM) reform H.R. 9096 (Pharmacists Fight Back Act), regarding Pharmacy Benefit Manager (PBM) reform, all provisions","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-17T14:28:01-04:00
3244550,386e0f7b-50dc-4582-b548-ed30d28c10c5,Q3,"TWENTY-FIRST CENTURY GROUP, INC.",38687,"CARDINAL HEALTH, INC.",2024,third_quarter,PHA,"Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; drug shortages; Food as Medicine; Drug Supply Chain Security Act (DSCSA), and the healthcare supply chain.","HOUSE OF REPRESENTATIVES,SENATE",24000,,0,0,2024-10-17T15:04:26-04:00
3244558,fc35851c-8022-4bb8-ada3-7142017298a7,Q3,MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP),24566,MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS,2024,third_quarter,PHA,"H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,640000,0,0,2024-10-17T15:05:08-04:00
3244820,0f613df5-6423-4a9b-a3df-bbf088a4b82c,Q3,NATIONAL RURAL LETTER CARRIERS' ASSOCIATION,28526,NATIONAL RURAL LETTER CARRIERS' ASSOCIATION,2024,third_quarter,PHA,"H.R. 6283,""DRUG Act""- legislation that impacts Pharmacy Benefit Managers (PBMs), it could have the unintended consequences of reducing mail volume and increasing the costs/premiums of employer sponsored health programs. The NRLCA has not taken a position on this legislation. S. 1542, ""DRUG Act""- Senate companion bill to H.R. 6283, the NRLCA has not taken a position on this bill.","HOUSE OF REPRESENTATIVES,SENATE",,125000,0,0,2024-10-17T15:30:17-04:00
3244907,69318c02-5db3-4c1a-b1c8-8a9ce740139d,Q3,WAXMAN STRATEGIES,401103693,340B HEALTH,2024,third_quarter,PHA,Issues affecting the 340B drug pricing program; Appropriations for 340B program.,"HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2024-10-17T15:38:53-04:00
3245154,8a2cbcab-a5fd-40be-a215-f061a91afa38,Q3,DENTONS US LLP,36105,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA,2024,third_quarter,PHA,Federal issues impacting workforce and innovation in the pharmaceutical industry.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-17T16:10:42-04:00
3245995,dc8ec398-c6b7-4e3e-8a5d-7343fc002a91,Q3,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,27478,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,2024,third_quarter,PHA,"H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542 / H.R. 6283, the Delinking Revenue from Unfair Gouging Act; H.R. 1173, the Patients Right to Know Their Medication Act of 2023; Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959); Implementation of Public Law 113-54, the Drug Quality and Security Act; Draft Guidance for Industry, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act, (Docket No. FDA-2015-D-3517); H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for ""Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act"" (Docket No. FDA-2023-N-4806); Request for Information on Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024; H.R.2882, the Further Consolidated Appropriations Act, 2024; Comments on implementation and enforcement of recent changes to USP Chapter <797>, regarding the Compounded Sterile Preparations (CSPs) in Category 3 to the FDA; Comments to FDA on ""Agency Information Collection Activities; Proposed Collection; Comment Request; Proposed Small Dispensers Assessment Under the Drug Supply Chain Security Act"" [Docket No.FDA-2024-N-0668]; Comments to FDA on "" Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act""[Docket No. FDA-2023-N-0061]; H.R.9096, the Pharmacists Fight Back Act; Comments to FDA on Docket No. FDA-2023-N-4806 - Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket; Request for Information and Comment.","Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,380000,0,0,2024-10-17T18:41:36-04:00
3246133,15bd7508-0788-4348-9554-c3b31743364d,Q3,BURRELL INTERNATIONAL GROUP LLC,401103483,TONIX PHARMACEUTICALS HOLDING CORP.,2024,third_quarter,PHA,"LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY25 Defense Appropriation for broad-spectrum antivirals, FY25 LHHS for long covid and cocaine overdose funding","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-17T20:00:53-04:00
3246134,86148853-2ea6-4bca-a1f8-e9559b4bc965,Q3,BURRELL INTERNATIONAL GROUP LLC,401103483,SHIONOGI INC.,2024,third_quarter,PHA,"FY25 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-17T20:01:42-04:00
3246209,561a562b-6355-4636-9109-e56031b24a7e,Q3,DA VINCI GROUP,11548,"BOESEN & SNOW, LLC",2024,third_quarter,PHA,"Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-10-17T20:33:55-04:00
3246262,60907bd4-389b-48be-8f19-57970b9cf499,Q3,FORBES-TATE,400976792,CALIFORNIA LIFE SCIENCES ASSOCIATION,2024,third_quarter,PHA,Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-17T20:45:34-04:00
3246304,efda9ea2-2f51-4a0a-97bd-c33e29a1dc7e,Q3,FORBES-TATE,400976792,PHRMA,2024,third_quarter,PHA,Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2024-10-17T20:55:14-04:00
3246326,272616ac-9f58-433b-b92d-2a0ea4977e42,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,"LILLY USA, LLC",2024,third_quarter,PHA,Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation H.R. 4818 Treat and Reduce Obesity Act,"HOUSE OF REPRESENTATIVES,SENATE",90000,,0,0,2024-10-17T20:58:44-04:00
3246369,7f2662d7-c51e-4166-88c6-b9fd9d7bfb18,Q3,E3 STRATEGIC CONSULTING GROUP,401104104,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2024,third_quarter,PHA,"Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023; H.R.830 - HELP Copays Act; S. 1542 - Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act""); HR 4895 - H.R. 4895: Lowering Drug Costs for American Families Act; H.R. 2880: Protecting Patients Against PBM Abuses Act; HR 6283 - The Drug Act; HR 5378 - Lower Costs, More Transparency Act","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-17T21:16:46-04:00
3246410,adb27fbe-1d48-44a0-ba21-0e8a9634b75c,Q3,"POLARIS GOVERNMENT RELATIONS, LLC",307730,CIGNA CORPORATION,2024,third_quarter,PHA,Drug pricing and issues facing the pharmacy benefit manager industry generally,"HOUSE OF REPRESENTATIVES,SENATE",90000,,0,0,2024-10-17T21:28:44-04:00
3246716,70a0fa19-cf6f-4acf-9905-943e500253ea,Q3,BALLARD PARTNERS,401104288,THE CRANEWARE GROUP (F.K.A. SENTRY DATA SYSTEMS),2024,third_quarter,PHA,340B Drug Discount Program.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-18T06:35:33-04:00
3246798,fb6cdc7e-fb8f-48fc-9d2c-0e118414b871,Q3,VAN SCOYOC ASSOCIATES,39837,ZEBRA TECHNOLOGIES CORP.,2024,third_quarter,PHA,"Temperature monitoring technology issues, as follows: H.R.8070, Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025 H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2025",HOUSE OF REPRESENTATIVES,30000,,0,0,2024-10-18T07:34:42-04:00
3246912,0e60e76f-6249-40b1-bb9a-a30e6ddef7d9,Q3,340B HEALTH,316434,340B HEALTH,2024,third_quarter,PHA,"The 340B Drug Pricing Program; H.R. 2534, The Protect 340B Act; FY24 and FY25 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bills. HR 3290,to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.3561 - PATIENT Act of 2023, The Stop Drug Shortages Act (Draft legislation- House), H.R. 5378: Lower Costs, More Transparency Act, S. 1182: 340B Reporting and Accountability Act; S.1133: 340B Accountability Act of 2023,S.1038: Drug Price Transparency in Medicaid Act of 2023,H.R.1613: Drug Price Transparency in Medicaid Act of 2023,H.R.198: Drug Pricing Transparency and Accountability Act; S. 2973: Modernizing and Ensuring PBM Accountability Act, Draft Senate legislation the SUSTAIN 340B Act, HR 7635 and S. 5021, the 340B PATIENTS Act.H.R. 8574, 340B ACCESS Act: H.R.8144 - Rural 340B Access Act of 2024","Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",,345454,0,0,2024-10-18T08:28:24-04:00
3246971,bf1cc0f8-b89b-429a-ad20-2907161e9592,Q3,AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION,1331,AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION,2024,third_quarter,PHA,"Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2630/S. 652, Safe Step Act. Support H.R. 167, Patient Access to Urgent-Use Pharmacy Compounding Act","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,1060000,0,0,2024-10-18T08:54:03-04:00
3247519,2298002a-6270-4767-8567-eead5cea783e,Q3,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2024,third_quarter,PHA,Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA),"Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",80000,,0,0,2024-10-18T10:13:04-04:00
3247558,f16638e0-a156-40da-b43c-6d51af33cb53,Q3,"CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC.",401103415,"CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC.",2024,third_quarter,PHA,strengthening the 340B program for childrens hospitals.,"HOUSE OF REPRESENTATIVES,SENATE",,80000,0,0,2024-10-18T10:16:24-04:00
3247901,375f6df0-9912-44e8-9a51-bb693c1aa52e,Q3,AKIN GUMP STRAUSS HAUER & FELD,682,CENTRIENT PHARMACEUTICALS LLC,2024,third_quarter,PHA,Issues related to onshoring supply chains and biomanufacturing of essential medicines to the United States.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE",30000,,0,0,2024-10-18T10:40:23-04:00